Clinical factors related to morbidity and mortality in high-risk heart failure patients

the GUIDE-IT predictive model and risk score

Christopher O'Connor, Mona Fiuzat, Hillary Mulder, Adrian Coles, Tariq Ahmad, Justin A. Ezekowitz, Kirkwood F. Adams, Ileana L. Pina, Kevin J. Anstrom, Lawton S. Cooper, Daniel B. Mark, David J. Whellan, James L. Januzzi, Eric S. Leifer, G. Michael Felker

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. Methods and results: The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan–Meier event rate 34.5% at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan–Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score. Conclusion: Risk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials. Clinical trial registration: ClinicalTrials.gov ID number NCT01685840.

Original languageEnglish (US)
JournalEuropean Journal of Heart Failure
DOIs
StatePublished - Jan 1 2019

Fingerprint

Heart Failure
Morbidity
Mortality
Hospitalization
Biomarkers
Clinical Trials
Natriuretic Peptides
Sleep Apnea Syndromes
Therapeutics
Hispanic Americans
Proportional Hazards Models
Hypotension
Myocardial Ischemia
Cause of Death
Creatinine
Patient Care
Heart Rate
Sodium
Phenotype
Equipment and Supplies

Keywords

  • Natriuretic peptides
  • Predictive risk model
  • Risk stratification
  • Systolic heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical factors related to morbidity and mortality in high-risk heart failure patients : the GUIDE-IT predictive model and risk score. / O'Connor, Christopher; Fiuzat, Mona; Mulder, Hillary; Coles, Adrian; Ahmad, Tariq; Ezekowitz, Justin A.; Adams, Kirkwood F.; Pina, Ileana L.; Anstrom, Kevin J.; Cooper, Lawton S.; Mark, Daniel B.; Whellan, David J.; Januzzi, James L.; Leifer, Eric S.; Felker, G. Michael.

In: European Journal of Heart Failure, 01.01.2019.

Research output: Contribution to journalArticle

O'Connor, C, Fiuzat, M, Mulder, H, Coles, A, Ahmad, T, Ezekowitz, JA, Adams, KF, Pina, IL, Anstrom, KJ, Cooper, LS, Mark, DB, Whellan, DJ, Januzzi, JL, Leifer, ES & Felker, GM 2019, 'Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score', European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1450
O'Connor, Christopher ; Fiuzat, Mona ; Mulder, Hillary ; Coles, Adrian ; Ahmad, Tariq ; Ezekowitz, Justin A. ; Adams, Kirkwood F. ; Pina, Ileana L. ; Anstrom, Kevin J. ; Cooper, Lawton S. ; Mark, Daniel B. ; Whellan, David J. ; Januzzi, James L. ; Leifer, Eric S. ; Felker, G. Michael. / Clinical factors related to morbidity and mortality in high-risk heart failure patients : the GUIDE-IT predictive model and risk score. In: European Journal of Heart Failure. 2019.
@article{f8570dc924604ee49c4b248728161629,
title = "Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score",
abstract = "Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. Methods and results: The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40{\%}) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan–Meier event rate 34.5{\%} at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan–Meier event rate 12.2{\%} at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score. Conclusion: Risk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials. Clinical trial registration: ClinicalTrials.gov ID number NCT01685840.",
keywords = "Natriuretic peptides, Predictive risk model, Risk stratification, Systolic heart failure",
author = "Christopher O'Connor and Mona Fiuzat and Hillary Mulder and Adrian Coles and Tariq Ahmad and Ezekowitz, {Justin A.} and Adams, {Kirkwood F.} and Pina, {Ileana L.} and Anstrom, {Kevin J.} and Cooper, {Lawton S.} and Mark, {Daniel B.} and Whellan, {David J.} and Januzzi, {James L.} and Leifer, {Eric S.} and Felker, {G. Michael}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ejhf.1450",
language = "English (US)",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Clinical factors related to morbidity and mortality in high-risk heart failure patients

T2 - the GUIDE-IT predictive model and risk score

AU - O'Connor, Christopher

AU - Fiuzat, Mona

AU - Mulder, Hillary

AU - Coles, Adrian

AU - Ahmad, Tariq

AU - Ezekowitz, Justin A.

AU - Adams, Kirkwood F.

AU - Pina, Ileana L.

AU - Anstrom, Kevin J.

AU - Cooper, Lawton S.

AU - Mark, Daniel B.

AU - Whellan, David J.

AU - Januzzi, James L.

AU - Leifer, Eric S.

AU - Felker, G. Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. Methods and results: The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan–Meier event rate 34.5% at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan–Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score. Conclusion: Risk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials. Clinical trial registration: ClinicalTrials.gov ID number NCT01685840.

AB - Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. Methods and results: The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan–Meier event rate 34.5% at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan–Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score. Conclusion: Risk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials. Clinical trial registration: ClinicalTrials.gov ID number NCT01685840.

KW - Natriuretic peptides

KW - Predictive risk model

KW - Risk stratification

KW - Systolic heart failure

UR - http://www.scopus.com/inward/record.url?scp=85063503492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063503492&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1450

DO - 10.1002/ejhf.1450

M3 - Article

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

ER -